Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
5.75
-0.09 (-1.54%)
Jun 18, 2025, 4:00 PM - Market closed

Serina Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-0.94-11.145.27-2.68-1.26
Depreciation & Amortization
0.190.190.090.060.03
Other Amortization
0.320.35---
Loss (Gain) From Sale of Assets
---0-0.03
Loss (Gain) From Sale of Investments
---0.010.01
Stock-Based Compensation
3.52.60.030.010.08
Other Operating Activities
-19.55-5.81-7.940.54-0.33
Change in Accounts Receivable
---01.27
Change in Accounts Payable
-1.46-1.660.39-0-0.37
Change in Unearned Revenue
0.070.07-0.15-1.61
Change in Other Net Operating Assets
-2-1.72-0.31-0.16-0.05
Operating Cash Flow
-19.88-17.14-2.48-2.08-2.25
Capital Expenditures
-0.01-0.02-0.5-0.01-0.08
Investment in Securities
---0.990.93
Investing Cash Flow
-0.01-0.02-0.50.980.82
Long-Term Debt Issued
-3.0410.15-
Long-Term Debt Repaid
--0.17-0.05-3.69-0.01
Net Debt Issued (Repaid)
0.492.8810.051.31-0.01
Issuance of Common Stock
10100.0201
Other Financing Activities
4.920.34---
Financing Cash Flow
15.413.2110.071.311.08
Net Cash Flow
-4.49-3.957.090.22-0.35
Free Cash Flow
-19.89-17.16-2.98-2.09-2.34
Free Cash Flow Margin
-39000.00%-30641.07%-94.51%-352.55%-67.41%
Free Cash Flow Per Share
-2.19-2.33-0.41-0.97-1.09
Cash Interest Paid
---0.020
Levered Free Cash Flow
-11.33-7.94-0.82-1.22-
Unlevered Free Cash Flow
-11.44-7.96-0.48-1.21-
Change in Net Working Capital
3.170.99-0.87-0.15-
Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q